Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 9

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 9
---
 Substantial Stockholder Value DVAX stock has returned +62% vs. XBI (7)% S&P Biotechnology Select Industry Index (XBI) 10 | 62% total stockholder return 1 ~65% HEPLISAV - B revenue CAGR 2 $300M+ of net income generated 3 $550M+ growth in cash and cash equivalents 4 $200M share repurchase program (~15% of market cap) 5 x x x x x 23 - May - 19 Announced strategic refocus on vaccine business / HEPLISAV - B launch 17 - Apr - 25 Dynavax f iled d efinitive proxy Since Our Strategic Pivot, Dynavax Has Generated Over $900 Million of Stockholder Value… … As Demonstrated By Our © Copyright DYNAVAX 2025 * from strategic pivot until definitive proxy filing * 1 Apr - 2025

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Analysts Have High Confidence In Management’s Ability to Execute and Focus on HEPLISAV - B… © Copyright DYNAVAX 2025 Nov 8, 2024 Citizens JMP ” We continue to be fans of the company’s best - in - class hepatitis B preventive vaccine , HEPLISAV - B, Dynavax’s progress to become cash - flow positive, and the potential for additional value creation by a team that has demonstrated it can “get it done ” Nov 7, 2024 William Blair ” [HEPLISAV - B] continues to show over 20% year - over - year growth , and management reiterated both near - and long - term guidance for the franchise, now expecting total market opportunity of over $900M in 2030. We continue to believe growth of the HEPLISAV - B franchise, potentially reaching over $550M annually, will drive upside to current share prices ” Feb 21, 2025 Citizens JMP “A key recent topic is Dynavax’s capital allocation strategy given the company’s strong balance sheet… Management has clearly been stringent in its evaluation, given no assets have been acquired to date… We believe the results of the Phase II shingles trial will better inform the near - term capital allocation strategy in gaining a better sense